Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efavirenz + nevirapine
- Development stage
- Discontinued
- Lead developer
- DuPont
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Efavirenz + nevirapine is a non-standard, off-label combination of two non-nucleoside reverse transcriptase inhibitors (NNRTIs) used in antiretroviral therapy for HIV infection. Both drugs act by inhibiting the reverse transcriptase enzyme of HIV, thereby preventing viral replication. Efavirenz is known for its central nervous system side effects and teratogenicity risk, while nevirapine carries risks of hepatotoxicity and severe rash. Standard first-line regimens typically use one NNRTI plus two nucleoside reverse transcriptase inhibitors (NRTIs), not both NNRTIs together; thus, this dual-NNRTI combination is not recommended or approved in major guidelines due to lack of evidence for added benefit and increased risk of toxicity[1][3]. Both drugs are widely used individually as part of three-drug regimens with NRTIs.
- Brand names
- Sustiva (efavirenz)Stocrin (efavirenz)Viramune (nevirapine)
- Other names
- NVP + EFV
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on efavirenz + nevirapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efavirenz + nevirapine.